Yes, marijuana is currently a Schedule I controlled substance under federal law. It has held that classification since Congress passed the Controlled Substances Act in 1970, placing it alongside heroin, LSD, and ecstasy. However, the Department of Justice proposed moving marijuana to Schedule III in May 2024, and that rulemaking process is ongoing.
What Schedule I Actually Means
The Controlled Substances Act sorts drugs into five schedules based on three factors: potential for abuse, whether the drug has an accepted medical use in the United States, and whether it can be used safely under medical supervision. Schedule I is the most restrictive tier. To land there, a substance must meet all three criteria: a high potential for abuse, no currently accepted medical use, and no accepted safety for use even with a doctor overseeing it.
That classification carries real consequences. Researchers who want to study Schedule I substances need a site-specific DEA investigator registration, which adds time and complexity to clinical trials. Doctors cannot prescribe Schedule I drugs. And businesses operating in the state-legal cannabis market face a punishing tax situation because of a provision in the tax code, Section 280E, that bars any business trafficking in Schedule I or II substances from deducting ordinary expenses like rent, wages, and marketing. State-licensed cannabis companies have faced effective tax rates exceeding 70% as a result.
Why the Classification Is Controversial
The central tension is the “no accepted medical use” requirement. In 2023, the FDA completed a review finding scientific support for marijuana’s use in treating pain, nausea and vomiting from chemotherapy, and anorexia related to medical conditions. More than 30,000 licensed healthcare practitioners across 43 U.S. jurisdictions are authorized to recommend medical marijuana to over 6 million registered patients for at least 15 medical conditions.
The federal government has also approved cannabis-related medications individually. Epidiolex, derived directly from cannabis, is FDA-approved for certain seizure disorders. Three synthetic cannabis-related drugs, Marinol, Syndros, and Cesamet, are also approved. The existence of these medications alongside marijuana’s Schedule I status has long struck critics as contradictory.
The Proposal to Move Marijuana to Schedule III
In May 2024, the Department of Justice published a notice of proposed rulemaking to transfer marijuana from Schedule I to Schedule III. The proposal followed a recommendation from the Department of Health and Human Services, which concluded that marijuana has a currently accepted medical use, a lower abuse potential than Schedule I and II drugs, and a likelihood of only moderate or low physical dependence with low psychological dependence.
Schedule III is a meaningful step down. Drugs in this category are recognized as having legitimate medical applications and a lower risk profile. Other Schedule III substances include testosterone, ketamine, and certain anabolic steroids. Moving marijuana here would not make it fully legal under federal law, but it would change the regulatory landscape significantly.
The proposal went through a public comment period, and the rulemaking process has not yet produced a final rule. Until that rule is finalized, marijuana remains Schedule I.
What Changes if Rescheduling Goes Through
The shift from Schedule I to Schedule III would affect taxes, research, and criminal penalties, though it would not legalize recreational use at the federal level.
- Taxes: Section 280E of the tax code would no longer apply to cannabis businesses, because it only covers Schedule I and II substances. State-legal operators could begin deducting standard business expenses like any other company. The DOJ has acknowledged this would have “unique economic impacts” and “large impacts related to Federal taxes.”
- Research: Scientists would no longer need the extra layer of Schedule I investigator registration to study marijuana. This would lower barriers to clinical trials and potentially accelerate the development of cannabis-based treatments.
- Criminal penalties: Federal trafficking penalties differ by schedule. For Schedule I marijuana offenses involving smaller quantities, a first offense carries a minimum of 5 years. For Schedule III drugs, the structure shifts: a first offense carries a maximum of 10 years with no mandatory minimum. The distinction matters most for people caught in federal enforcement actions.
What Rescheduling Would Not Change
Rescheduling to Schedule III would not make marijuana legal to buy or sell recreationally under federal law. It would still be a controlled substance, still regulated by the DEA, and still subject to federal enforcement. The patchwork of state laws, where some states allow recreational use, others permit only medical use, and a few still prohibit it entirely, would remain in place. Federal and state law would continue to conflict in states with legal markets, though the practical severity of that conflict would be reduced.
It also would not automatically allow doctors to write prescriptions for marijuana the way they do for other Schedule III drugs. The FDA would still need to approve specific marijuana products through its standard drug approval process before they could be prescribed in a pharmacy setting. The state-by-state medical marijuana recommendation system, where doctors authorize use rather than write traditional prescriptions, would likely continue as the primary access point for patients.